快速检索:        
    
在线办公系统
在线期刊
下载专区
排行榜
友情链接
扫描微信二维码,获取更多信息
徐浩,史大卓,陈可冀,马晓昌,毛节明,吕树铮,陈明哲.芎芍胶囊预防冠状动脉介入治疗后再狭窄的临床研究[J].中国中西医结合杂志,2000,(7):494-497
芎芍胶囊预防冠状动脉介入治疗后再狭窄的临床研究
Clinical Effect of Xiongshao Capsule on Preventing Restenosis Post-PTCA or/and Stenting
免费下载全文  查看/发表评论  下载PDF阅读器
  
DOI:
中文关键词:  芍芍胶囊  血管成形术  支架  再狭窄
英文关键词:Xiongshao capsule  angiography  stenting  restenosis
基金项目:国家“九五”攻关课题部分内容!(No.96-906-06-01)
作者单位
徐浩 XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 
史大卓 XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 
陈可冀 XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 
马晓昌 XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 
毛节明 XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 
吕树铮 XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 
陈明哲 XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 
摘要点击次数: 1406
全文下载次数: 1305
中文摘要:
      目的:观察芎芍胶囊预防冠状动脉介入治疗后再狭窄的临床疗效。方法:65例经皮冠状动脉腔内成形术(PTCA)或(及)支架植入术成功的冠心病患者,随机分为西药常规治疗(对照)组37例和西药常规加芍芍胶囊治疗(加中药)组28例。对患者术后6个月的心绞痛复发、血瘀证积分值变化、冠脉造影等进行随访观察。结果:加中药组心绞痛复发率显著低于对照组(P<0.05)。两组患者共有26例复查冠脉造影,其中加中药组10例中,再狭窄4例;对照组16例中,再狭窄13例,两组比较再狭窄发生率有显著性差异(P<0.05)。治疗后血瘀证积分值(分)加中药组(16.89±5.45)与对照组(21.41±4.98)比较有显著性差异( P< 0. 01)。Logistic回归分析发现,加用中药及术前血瘀证积分值是再狭窄发生与否的重要影响因素(P<0.05)。血瘀证积分值>25较血瘀证积分值≤25的患者再狭窄发生的比数比为6.5。结论:芎芍胶囊可明显降低冠状动脉介入治疗后的冠脉造影随访再狭窄的发生,减少心绞痛复发并改善患者的血瘀状态;血瘀证的轻重程度是冠状动脉介入治疗后再狭窄发生与否的重要影响因素,其积分值>25可考虑作为冠状动脉介入治疗后再狭窄发生的
英文摘要:
      To evaluate the effect of Xiongshao capsule (XSC) in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Methods: Sixty-five coronary heart disease (CHD) patients with successful angioplasty or and stenting were randomly divided into the control group (37 cases, routine treatment) and the XSC group (28 cases, routine treatment plus XSC). The recurrent of angina, changing of blood stasis syndrome score (BSSS) and coronary angiography within 6 months after coronary angioplasty or/ and stenting were observed. Results: Recurrent angina occurred in 6 out of 28 patients in the XSC group, which was much better than that in the control group, 18 out of 37 patients (P< 0. 05). Follow-up angiography was performed in 26 including 10 patients in the XSC group (restenosis was observed in 4 cases), and 16 cases in the control group (restenosis in 13 cases), there was significant difference between the XSC group and the control group (P< 0. 05). For BSSS at follow-up, XSC group was much lower than that of the control group (P < 0. 01). Logistic regress analysis showed the combination with XSC and the base-line BSSS were important affecting factors on the occurrence of restenosis (P < 0. 05 ). The odds ratio of the occurrence of angiographic restenosis (BSSS > 25 to BSSS≤25 ) was 6. 5. Conclusions: XSC could markedly reduce the occurrence of restenosis recurrence of angina and improve the condition of blood stasis after coronary angioplasty or/and stenting. The seventy of blood stasis syndrome was an important affecting factor on the occurrence of restenosis. BSSS >25 can be served as one of the predicting factors of the occurrence of restenosis after coronary angioplasty or/and stenting.
关闭